SK bioscience Co.,Ltd. (KRX:302440)
South Korea · Delayed Price · Currency is KRW 33,150
-1,450 (-4.19%)
Oct 23, 2026, 3:30 PM KST
SK bioscience Revenue
SK bioscience had revenue of 155.71B KRW in the quarter ending June 30, 2026, a decrease of -3.80%. This brings the company's total for the last twelve months to 659.27B, up 23.25% year-over-year. In the year 2025, SK bioscience had annual revenue of 651.37B with 143.46% growth. That makes SK bioscience the 11,267th largest company in the world by revenue and 528th in South Korea.
Revenue (ttm)
659.27B
Revenue Growth
+23.25%
P/S Ratio
3.92
Revenue / Employee
718.94M
Employees
917
Market Cap
2.59T
Revenue by Geography
- Europe 401.38B 61.6%
- South Korea 140.12B 21.5%
- America 98.37B 15.1%
- Asia 10.23B 1.6%
- Middle East 1.27B 0.2%
Fiscal year ended Dec 31, 2025 See the full SK bioscience breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 651.37B | 383.82B | 143.46% |
| Dec 31, 2024 | 267.55B | -101.96B | -27.59% |
| Dec 31, 2023 | 369.51B | -87.22B | -19.10% |
| Dec 31, 2022 | 456.73B | -472.28B | -50.84% |
| Dec 31, 2021 | 929.00B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Epis Holdings | 1.51T |
| SK Biopharmaceuticals | 861.34B |
| Hugel | 479.57B |
| LigaChem Biosciences | 98.78B |
| HLB Co., Ltd. | 97.47B |
| ABL Bio | 34.28B |
| OliX Pharmaceuticals | 13.64B |
| Peptron | 6.00B |